You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 9, 2026

Claims for Patent: 12,453,756

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,453,756

Title:	GIP/GLP1 agonist compositions
Abstract:	A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.
Inventor(s):	Vincent John Corvari, Christopher Sears Minie, Dinesh Shyamdeo Mishra, Ken Kangyi Qian
Assignee:	Eli Lilly and Co
Application Number:	US19/042,887
Patent Claims:	1. A pharmaceutical composition comprising: (a) tirzepatide, or a pharmaceutically acceptable salt thereof; and (b) from about 6.2 mg/mL to about 9.5 mg/mL of NaCl, wherein the pharmaceutical composition has a pH of from about 6.5 to about 7.5. 2. The pharmaceutical composition of claim 1, wherein the composition comprises from about 7.0 mg/mL to about 9.0 mg/ml of NaCl. 3. The pharmaceutical composition of claim 1, wherein the composition has a pH of from about 6.7 to about 7.3. 4. The pharmaceutical composition of claim 1, wherein the composition comprises from about 5 mg/mL to about 30 mg/mL of tirzepatide, or a pharmaceutically acceptable salt thereof. 5. The pharmaceutical composition of claim 1, wherein the composition further comprises a preservative selected from the group consisting of metacresol and phenol. 6. The pharmaceutical composition of claim 1, wherein the composition is administered using an automatic injection apparatus. 7. The pharmaceutical composition of claim 2, wherein the composition comprises about 8.2 mg/ml of NaCl. 8. The pharmaceutical composition of claim 4, wherein the composition comprises 5 mg/mL, 10 mg/mL, 15 mg/mL, 20 mg/mL, 25 mg/mL, or 30 mg/mL of tirzepatide, or a pharmaceutically acceptable salt thereof. 9. The pharmaceutical composition of claim 5, wherein the preservative is metacresol. 10. The pharmaceutical composition of claim 5, wherein the preservative is phenol. 11. The pharmaceutical composition of claim 9, wherein the composition comprises from about 2.0 mg/mL to about 4.0 mg/mL of metacresol. 12. The pharmaceutical composition of claim 11, wherein the composition comprises about 3.15 mg/mL of metacresol. 13. The pharmaceutical composition of claim 10, wherein the composition comprises from about 3.0 mg/mL to about 7.0 mg/ml of phenol. 14. The pharmaceutical composition of claim 13, wherein the composition comprises about 5.0 mg/mL of phenol.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.